Ovarian steroids: The good, the bad, and the signals that raise them

Cell Cycle

Volumn 5, Issue 11, 2006, Pages 1178-1183

  Jamnongjit, Michelle ^a   Hammes, Stephen R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Follicle; Oocyte; Ovary; Receptor; Steroid

Indexed keywords

ANDROGEN; ANTIGESTAGEN; AROMATASE; CYCLIC AMP; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; GONADOTROPIN; LUTEINIZING HORMONE; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C; PROGESTERONE; SOMATOMEDIN; STEROID; STEROIDOGENIC ACUTE REGULATORY PROTEIN;

EXPERIMENTAL MODEL; GRANULOSA CELL; HORMONE ACTION; INFERTILITY; LUTEINIZATION; NONHUMAN; OOCYTE MATURATION; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OVULATION; REVIEW; STEROIDOGENESIS; THECA CELL;

ANIMALIA;

EID: 33744933179     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.11.2803     Document Type: Review

References (73)

1. Schomberg DW, Couse JF, Mukherjee A, Lubahn DB, Sar M, Mayo KE, Korach KS. Targeted disruption of the estrogen receptor-alpha gene in female mice: Characterization of ovarian responses and phenotype in the adult. Endocrinology 1999; 140:2733-44.
2. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998; 95:15677-82.
3. Couse JF, Korach KS. Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Ann Endocrinol (Paris) 1999; 60:143-8.
4. Hillier SG, Tetsuka M. Role of androgens in follicle maturation and atresia. Baillieres Clin Obstet Gynaecol 1997; 11:249-60.
5. Hu YC, Wang PH, Yeh S, Wang RS, Xie C, Xu Q, Zhou X, Chao HT, Tsai MY, Chang C. Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci USA 2004; 101:11209-14.
6. Shiina H, Matsumoto T, Sato T, Igarashi K, Miyamoto J, Takemasa S, Sakari M, Takada I, Nakamura T, Metzger D, Chambon P, Kanno J, Yoshikawa H, Kato S. From the Cover: Premature ovarian failure in androgen receptor-deficient mice. Proc Natl Acad Sci USA 2006; 103:224-9.
7. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery Jr CA, Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995; 9:2266-78.
8. Lobo RA. What are the key features of importance in polycystic ovary syndrome? Fertil Steril 2003; 80:259-61.
9. Wood JR, Strauss IIIrd JF. Multiple signal transduction pathways regulate ovarian steroidogenesis. Rev Endocr Metab Disord 2002; 3:33-46.
10. Havelock JC, Rainey WE, Carr BR. Ovarian granulosa cell lines. Mol Cell Endocrinol 2004; 228:67-78.
11. Piquette GN, LaPolt PS, Oikawa M, Hsueh AJ. Regulation of luteinizing hormone receptor messenger ribonucleic acid levels by gonadotropins, growth factors, and gonadotropin-releasing hormone in cultured rat granulosa cells. Endocrinology 1991; 128:2449-56.
12. Conneely OM, Lydon JP, De Mayo F, O'Malley BW. Reproductive functions of the progesterone receptor. J Soc Gynecol Investig 2000; 7:S25-32.
13. Jamnongjit M, Gill A, Hammes SR. Epidermal growth factor receptor signaling is required for normal ovarian steroidogenesis and oocyte maturation. Proc Natl Acad Sci USA 2005; 102:16257-61.
14. Hasegawa T, Zhao L, Caron KM, Majdic G, Suzuki T, Shizawa S, Sasano H, Parker KL. Developmental roles of the steroidogenic acute regulatory protein (StAR) as revealed by StAR knockout mice. Mol Endocrinol 2000; 14:1462-71.
15. Bose HS, Sato S, Aisenberg J, Shalev SA, Matsuo N, Miller WL. Mutations in the steroidogenic acute regulatory protein (StAR) in six patients with congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85:3636-9.
16. Strauss IIIrd JF, Kallen CB, Christenson LK, Watari H, Devoto L, Arakane F, Kiriakidou M, Sugawara T. The steroidogenic acute regulatory protein (StAR): A window into the complexities of intracellular cholesterol trafficking. Recent Prog Horm Res 1999; 54:369-94, (discussion 94-5).
17. Rajagopalan-Gupta RM, Lamm ML, Mukherjee S, Rasenick MM, Hunzicker-Dunn M. Luteinizing hormone/choriogonadotropin receptor-mediated activation of heterotrimeric guanine nucleotide binding proteins in ovarian follicular membranes. Endocrinology 1998; 139:4547-55.
18. Leung PC, Steele GL. Intracellular signaling in the gonads. Endocr Rev 1992; 13:476-98.
19. Seger R, Hanoch T, Rosenberg R, Dantes A, Merz WE, Strauss 3rd JF, Amsterdam A. The ERK signaling cascade inhibits gonadotropin-stimulated steroidogenesis. J Biol Chem 2001; 276:13957-64.
20. Cameron MR, Foster JS, Bukovsky A, Wimalasena J. Activation of mitogen-activated protein kinases by gonadotropins and cyclic adenosine 5′-monophosphates in porcine granulosa cells. Biol Reprod 1996; 55:111-9.
21. Gyles SL, Burns CJ, Whitehouse BJ, Sugden D, Marsh PJ, Persaud SJ, Jones PM. ERKs regulate cyclic AMP-induced steroid synthesis through transcription of the steroidogenic acute regulatory (StAR) gene. J Biol Chem 2001; 276:34888-95.
22. Chaturvedi G, Arai K, Limback D, Roby KF, Terranova PF. Src tyrosine kinase regulates CYP17 expression and androstenedione secretion in theca-enriched mouse ovarian cells. Endocrine 2004; 25:147-54.
23. Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, Asano T, Fujishiro M, Legro RS, Kimball SR, Strauss IIIrd JF, McAllister JM. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol 2005; 19:379-90.
24. Sekar N, Lavoie HA, Veldhuis JD. Concerted regulation of steroidogenic acute regulatory gene expression by luteinizing hormone and insulin (or insulin-like growth factor I) in primary cultures of porcine granulosa-luteal cells. Endocrinology 2000; 141:3983-92.
25. Demeestere I, Gervy C, Centner J, Devreker F, Englert Y, Delbaere A. Effect of insulin-like growth factor-I during preantral follicular culture on steroidogenesis, in vitro oocyte maturation, and embryo development in mice. Biol Reprod 2004; 70:1664-9.
26. Hirakawa T, Minegishi T, Abe K, Kishi H, Ibuki Y, Miyamoto K. A role of insulin-like growth factor I in luteinizing hormone receptor expression in granulosa cells. Endocrinology 1999; 140:4965-71.
27. LaVoie HA, Garmey JC, Veldhuis JD. Mechanisms of insulin-like growth factor I augmentation of follicle-stimulating hormone-induced porcine steroidogenic acute regulatory protein gene promoter activity in granulosa cells. Endocrinology 1999; 140:146-53.
28. Pierce KL, Luttrell LM, Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001; 20:1532-9.
29. Herrlich A, Daub H, Knebel A, Herrlich P, Ulrich A, Schultz G, Gudermann T. Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. Proc Natl Acad Sci USA 1998; 95:8985-90.
30. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, Lefkowitz RJ, Luttrell LM. The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 2000; 275:9572-80.
31. Manna PR, Huhtaniemi IT, Wang XJ, Eubank DW, Stocco DM. Mechanisms of epidermal growth factor signaling: Regulation of steroid biosynthesis and the steroidogenic acute regulatory protein in mouse Leydig tumor cells. Biol Reprod 2002; 67:1393-404.
32. Ascoli M, Segaloff DL. Regulation of the differentiated functions of Leydig tumor cells by epidermal growth factor. Ann NY Acad Sci 1989; 564:99-115.
33. Jezova M, Scsukova S, Nagyova E, Vranova J, Prochazka R, Kolena J. Effect of intraovarian factors on porcine follicular cells: Cumulus expansion, granulosa and cumulus cell progesterone production. Anim Reprod Sci 2001; 65:115-26.
34. Park JY, Su YQ, Ariga M, Law E, Jin SL, Conti M. EGF-like growth factors as mediators of LH action in the ovulatory follicle. Science 2004; 303:682-4.
35. Enien WM, Chantler E, Seif MW, Elstein M. Human ovarian granulosa cells and follicular fluid indices: The relationship to oocyte maturity and fertilization in vitro. Hum Reprod 1998; 13:1303-6.
36. Ben-Rafael Z, Mastroianni Jr L, Meloni F, Lee MS, Flickinger GL. Total estradiol, free estradiol, sex hormone-binding globulin, and the fraction of estradiol bound to sex hormone-binding globulin in human follicular fluid. J Clin Endocrinol Metab 1986; 63:1106-11.
37. Martin B, Rotten D, Jolivet A, Gautray JP. Binding of steroids by proteins in follicular fluid of the human ovary. J Clin Endocrinol Metab 1981; 53:443-7.
38. Phocas I, Mantzavinos T, Sarandakou A, Dimitriadou F, Zourlas PA. Serum and follicular fluid sex hormone-binding globulin in stimulated and unstimulated cycles. J Assist Reprod Genet 1995; 12:348-53.
39. Stouffer RL. Progesterone as a mediator of gonadotrophin action in the corpus luteum: Beyond steroidogenesis. Hum Reprod Update 2003; 9:99-117.
40. Loutradis D, Bletsa R, Aravantinos L, Kallianidis K, Michalas S, Psychoyos A. Preovulatory effects of the progesterone antagonist mifepristone (RU486) in mice. Hum Reprod 1991; 6:1238-40.
41. Robker RL, Russell DL, Espey LL, Lydon JP, O'Malley BW, Richards JS. Progesterone-regulated genes in the ovulation process: ADAMTS-1 and cathepsin L proteases. Proc Natl Acad Sci USA 2000; 97:4689-94.
42. Huynh K, Jones G, Thouas G, Britt KL, Simpson ER, Jones ME. Estrogen is not directly required for oocyte developmental competence. Biol Reprod 2004; 70:1263-9.
43. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudo-hermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 1994; 78:1287-92.
44. Hillier SG, de Zwart FA. Androgen/antiandrogen modulation of cyclic AMP-induced steroidogenesis during granulosa cell differentiation in tissue culture. Mol Cell Endocrinol 1982; 28:347-61.
45. Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, Huang KE, Lin H, Yeh SD, Altuwaijri S, Zhou X, Xing L, Boyce BF, Hung MC, Zhang S, Gan L, Chang C. Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA 2002; 99:13498-503.
46. White SN, Jamnongjit M, Gill A, Lutz LB, Hammes SR. Specific modulation of nongenomic androgen signaling in the ovary. Steroids 2005; 70:352-60.
47. Lutz LB, Jamnongjit M, Yang WH, Jahani D, Gill A, Hammes SR. Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands. Mol Endocrinol 2003; 17:1106-16.
48. Gill A, Jamnongjit M, Hammes SR. Androgens promote maturation and signaling in mouse oocytes independent of transcription: A release of inhibition model for mammalian oocyte meiosis. Mol Endocrinol 2004; 18:97-104.
49. Lieberman ME, Tsafriri A, Bauminger S, Collins WP, Ahren K, Lindner HR. Oocytic meiosis in cultured rat follicles during inhibition of steroidogenesis. Acta Endocrinol (Copenh) 1976; 83:151-7.
50. Yamashita Y, Shimada M, Okazaki T, Maeda T, Terada T. Production of progesterone from de novo-synthesized cholesterol in cumulus cells and its physiological role during meiotic resumption of porcine oocytes. Biol Reprod 2003; 68:1193-8.
51. Teissier MP, Chable H, Paulhac S, Aubard Y. Comparison of follicle steroidogenesis from normal and polycystic ovaries in women undergoing IVF: Relationship between steroid concentrations, follicle size, oocyte quality and fecundability. Hum Reprod 2000; 15:2471-7.
52. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of noninsulin-dependent diabetes mellitus. J Clin Invest 1995; 96:520-7.
53. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165-74.
54. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774-800.
55. Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 2003; 80:255-8.
56. Azziz R. Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 2003; 80:252-4.
57. Dunaif A. Hyperandrogenemia is necessary but not sufficient for polycystic ovary syndrome. Fertil Steril 2003; 80:262-3.
58. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999; 28:361-78.
59. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617-23.
60. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82:4075-9.
61. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876-80.
62. Seli E, Duleba AJ. Treatment of PCOS with metformin and other insulin-sensitizing agents. Curr Diab Rep 2004; 4:69-75.
63. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18:1210-8.
64. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24:633-67.
65. Pache TD, Chadha S, Gooren LJ, Hop WC, Jaarsma KW, Dommerholt HB, Fauser BC. Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome? Histopathology 1991; 19:445-52.
66. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: A secret program of the German Democratic Republic government. Clin Chem 1997; 43:1262-79.
67. Speiser PW. Congenital adrenal hyperplasia: Transition from chil dhood to adulthood. J Endocrinol Invest 2001; 24:681-91.
68. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60:241-9.
69. Rittmaster RS. Antiandrogen treatment of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28:409-21.
70. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: Evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000; 85:4047-52.
71. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83:99-102.
72. Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 2001; 179:39-46.
73. Qin KN, Rosenfield RL. Role of cytochrome P450c17 in polycystic ovary syndrome. Mol Cell Endocrinol 1998; 145:111-21.